Podcast Pearls
Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations

Download this PDF resource with summary points from a podcast episode featuring Sara Tinsley, PhD, APRN, AOCN, discussing the use of targeted therapies in patients with FLT3 or IDH1/2 mutated AML
Sara Tinsley, PhD, APRN, AOCN
Format: Adobe Acrobat (.pdf)
File Size: 900 KB
Released: January 6, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AbbVie

Information on this Educational Activity

Faculty

Sara Tinsley, PhD, APRN, AOCN

Nurse Practitioner
Courtesy Assistant Professor

Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

Sara M. Tinsley, PhD, APRN, AOCN, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Incyte, and Taiho and fees for non-CME services from Astellas, Bristol-Myers Squibb, and Incyte.

Program Medium

This program has been made available online.

Related Content

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the diagnosis and staging of light-chain amyloidosis

Shaji K. Kumar, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the initial management of light-chain amyloidosis

Vaishali Sanchorawala, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the management of light-chain amyloidosis at relapse

Ankit Kansagra, MD Released: January 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings